Cladribine regimen for treating multiple sclerosis
US9925151B2 · kind B2 · utility
2Cited by
22References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2007 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Feb 1, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.